LIVN — LivaNova PLC stock price and chart

Share this page

LIVN

$77.58-1.17%

as of close, Oct 16, 2026

☾ AH $77.58 -1.17%

LivaNova PLCStock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.01%Russell 3000 0.006%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

40.050.060.070.080.090.0100.0110.0120.0130.005.0M10.0M$77.58

2026-10-16

Price$77.58

MA20$77.25

MA50$66.92

Vol3.9M

What would $1,000 invested in LIVN be worth today? →

LIVN returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $77.58
YTD price return: +26.08%
YTD total return: +26.08%
Next earnings: Nov 4, 2026 · Before open
Market cap: 4.3B2016-12 2.2B2026-10 4.3B+94.9% over the window
Enterprise value: 4.1B
Shares outstanding: 55.1M2016-06 49.1M2026-06 55.1M+12.3% over the window
52W low: $48.82
52W high: $85.76
From 52W high: -9.54%
From 52W low: +58.91%
52W range: 78%

Volume

Rel volume: 1.21×
30D volume: 642.2K
30D $ vol: 49.7M

Fundamentals

Sales (ttm): 1.5B2016-12 964.9M2026-06 1.5B+52.5% over the window
Sales/share: $26.712016-12 $20.032026-06 $26.71+33.4% over the window
EPS (ttm): $3.402016-12 -$1.282026-06 $3.40-365.5% over the window
FCF (ttm): 148.3M2016-12 51.8M2026-06 148.3M+186.4% over the window
FCF/share: $2.692016-12 $1.072026-06 $2.69+150.4% over the window
Book value/share: $24.062016-06 $37.172026-06 $24.06-35.3% over the window
Net margin: 12.81%2016-12 -6.5%2026-06 12.8%-296.9% over the window
ROE: 14.23%2016-12 -3.7%2026-06 14.2%-486.8% over the window
ROA: 7.14%2016-12 -2.7%2026-06 7.1%-366.4% over the window
Debt / equity: 0.22×2016-06 0.052026-06 0.22+379.1% over the window
Current ratio: 1.452016-06 1.932026-06 1.45-24.7% over the window

Growth (CAGR, ttm) · 10Y

Sales: +12.40%2025-06-30 → 2026-06-301.3B → 1.5B (+12.4% total)+10.70%2023-06-30 → 2026-06-301.1B → 1.5B (+35.7% total)+8.93%2021-03-31 → 2026-06-30939.4M → 1.5B (+56.6% total)+4.55%2016-12-31 → 2026-06-30964.9M → 1.5B (+52.5% total)
FCF: -8.51%2025-06-30 → 2026-06-30162.1M → 148.3M (-8.5% total)+72.98%2023-06-30 → 2026-06-3028.6M → 148.3M (+417.8% total)+62.89%2021-03-31 → 2026-06-3011.5M → 148.3M (+1194.6% total)+11.72%2016-12-31 → 2026-06-3051.8M → 148.3M (+186.4% total)
Shares: +0.90%2025-06-30 → 2026-06-3054.6M → 55.1M (+0.9% total)+0.74%2023-06-30 → 2026-06-3053.9M → 55.1M (+2.2% total)+2.32%2021-03-31 → 2026-06-3048.9M → 55.1M (+12.8% total)+1.16%2016-06-30 → 2026-06-3049.1M → 55.1M (+12.3% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +11.39%2025-06-30 → 2026-06-30$23.98 → $26.71 (+11.4% total)+9.88%2023-06-30 → 2026-06-30$20.13 → $26.71 (+32.7% total)+6.46%2021-03-31 → 2026-06-30$19.23 → $26.71 (+38.9% total)+3.08%2016-12-31 → 2026-06-30$20.03 → $26.71 (+33.4% total)
FCF/share: -9.33%2025-06-30 → 2026-06-30$2.97 → $2.69 (-9.3% total)+71.70%2023-06-30 → 2026-06-30$0.53 → $2.69 (+406.4% total)+59.20%2021-03-31 → 2026-06-30$0.23 → $2.69 (+1048.0% total)+10.15%2016-12-31 → 2026-06-30$1.07 → $2.69 (+150.4% total)
Book value/share: +16.99%2025-06-30 → 2026-06-30$20.56 → $24.06 (+17.0% total)+1.47%2023-06-30 → 2026-06-30$23.02 → $24.06 (+4.5% total)+2.08%2021-03-31 → 2026-06-30$21.60 → $24.06 (+11.4% total)-4.26%2016-06-30 → 2026-06-30$37.17 → $24.06 (-35.3% total)
Price: +44.00%2025-10-16 → 2026-10-16$53.89 → $77.58 (+44.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+16.73%2023-10-16 → 2026-10-16$48.77 → $77.58 (+59.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-1.55%2021-10-15 → 2026-10-16$83.89 → $77.58 (-7.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+3.23%2016-10-14 → 2026-10-16$56.45 → $77.58 (+37.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +44.00%2025-10-16 → 2026-10-16$53.89 → $77.58 (+44.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+16.73%2023-10-16 → 2026-10-16$48.77 → $77.58 (+59.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-1.55%2021-10-15 → 2026-10-16$83.89 → $77.58 (-7.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+3.23%2016-10-14 → 2026-10-16$56.45 → $77.58 (+37.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 22.8×2016-12 38.652026-10 22.67-41.3% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 22.8×2016-12 24.952026-10 22.80-8.6% over the window
Fwd P/E: 16.3×
P/S (ttm)Market cap ÷ TTM revenue.: 2.9×2016-12 7.302026-10 2.91-60.2% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.2×2016-12 1.212026-10 3.23+167.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 28.8×2016-12 29.742026-10 28.83-3.1% over the window
EV/EBITDA (fy): 17.1×
EV/Sales (ttm): 2.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 3.47%2016-12 2.4%2026-06 3.3%+38.6% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 55.1M ÷ 54.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.90%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.90%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2.5B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -0.90%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($4.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-12 2.5%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($4.3B). Same caveat as the cash buyback yield.: 0.00%2016-12 2.5%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/OI: 32nd
P/S: 49th
P/B: 84th
P/FCF: 22nd

Bar = where today’s multiple sits in LIVN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-1.17%

+1.56%

-1.18%

-5.15%

YTD

+26.08%

+43.96%

-7.52%

Financial statements

Open full LIVN financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

LIVN — LivaNova PLC price, chart and key statistics